Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical ...

Hangzhou ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased ...

Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced ...

Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...

MONTREAL, CANADA – Pfizer Canada’s pharmaceutical division is among Canada’s best companies to work for, says a closely watched annual survey by Report on Business Magazine. The magazine, published by ...

Pfizer faces a significant patent cliff, pricing reforms, and limited financial flexibility from high debt, all threatening future earnings growth. Weak share price momentum and sector ...

Pfizer stands as one of the largest drug makers in the world. It faces normal industry challenges, but it also has a lofty payout ratio. Its latest acquisition shows what it is capable of doing to get ...

The experiences of Svedka, Alaska Airlines and Avocados From Mexico offer marketers a valuable reality check on the progress of AI-powered creative tools.

Pfizer (PFE) stock hold rating: 2026 patent cliff, falling Covid sales, GLP-1 obesity timeline, and M&A integration risks—read the outlook now.

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of ...